28th March 2019 - Phio and Glycostem to Collaborate on Use of its sd-rxRNA® platform and Glycostem's oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment
Glycostem partners with Marie Curie
December 2018 - Glycostem is proud to be commercial partner in the Marie Curie “Mature-NK” programme. The funding for the CAR-NK technology will be well invested.
Glycostem technology is awarded research grant
December 2018 - Together with Enpicom Glycostem has been awarded funding to develop cancer prediction tool for an area without standard therapy.
Eurostars Granted Project
16th May 2018 - Eurostars, a European joint programme, co-funded from the national budgets of several EUREKA countries and by the European Union through Horizon 2020 has awarded,through a highly-competitive selection process,the Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumour
Glycostem Clinical Data Recap
January 2018 - In August of 2017, Clinical Cancer Research published a report on the positive outcome of Glycostem’s NK-killer cells phase I clinical trial, which was carried out at Radboud University Center in the Netherlands.
Lupus Ventures Takes Stake in Glycostem
December 2017 - Netherlands-based Lupus Ventures has invested €3 million in Glycostem, furthering the company’s expansion and ongoing technological development. Glycostem will channel this funding primarily to production optimisation and automation.